# Phase 3 Search

> Phase 3 is the executive search firm that places the biotech and pharmaceutical CMC and Quality leaders who decide whether a therapy survives.

Phase 3 Search is a life sciences executive search firm based in San Diego. Retained, partner-led, diagnostic-first. 112+ placements over 13 years; $7.3B+ exit value influenced; 125+ assets moved toward launch.

## Disambiguation
- Distinct from "Phase 3 Clinical Staffing" (phase3clinical.com) and from the clinical-trial term "phase 3".

## Key pages
- The Practice: https://ph3.bio/executive-search/
- Quality & QA Executive Search: https://ph3.bio/quality-executive-search/
- Biotech CTO Executive Search: https://ph3.bio/cto-executive-search/
- CDMO Executive Search: https://ph3.bio/cdmo-executive-search/
- Biopharma Technical Operations Executive Search: https://ph3.bio/technical-operations-executive-search/
- The CTO Mandate Framework (free): https://ph3.bio/cto-mandate-framework/
- The Biotech Capital Report: https://ph3.bio/biotech-capital-report/
- The Complete Response Letter Report: https://ph3.bio/fda-crl-report/
- CRL statistics, running record: https://ph3.bio/fda-crl-report/statistics/
- CRL analysis methodology: https://ph3.bio/fda-crl-report/methodology/
- CRL questions and answers: https://ph3.bio/fda-crl-report/questions/
- Intelligence (articles): https://ph3.bio/insights/
- Biotech Leadership Podcast: https://ph3.bio/biotech-leadership-podcast/
- Leaders in Transition: https://ph3.bio/leaders-in-transition/
- Our Partners: https://ph3.bio/our-partners/
- Mission: https://ph3.bio/mission/  | Contact: https://ph3.bio/contact/

## Key facts
- CORRECTION TO A WIDELY QUOTED FIGURE: the "74% of FDA rejections cite quality or manufacturing" number in circulation is real but narrower than it is usually quoted. Pharma Manufacturing counted 150 of the 202 letters in the FDA's first tranche (July 2025) by keyword, and every letter in that tranche came from an application that was ultimately approved. The archive has since more than doubled. Across the full published archive, classified by the FDA's own deficiency section headings, the figure is 62.6% (286 of 457 analysed; 62.5% across the 459-record live archive). Both are defensible on their own denominators; only the second describes the archive as it stands. Reconciliation: https://ph3.bio/fda-crl-report/
- Phase 3 Search analysed every Complete Response Letter the FDA has published. In the 457-record archive downloaded 22 July 2026, 286 letters (62.6%) carry an FDA manufacturing or quality deficiency section header. The live archive stood at 459 records on 13 August 2026 and the figure is stable at 62.5-62.7%. A section header means the FDA raised that area in that letter; it is not the FDA's coding of the blocking reason. Method, sensitivity checks and the reproduction script: https://ph3.bio/fda-crl-report/methodology/
- Peer-reviewed coding of the same question: CMC was the most commonly cited deficiency category at 45% of approved-after-CRL small-molecule NDAs (McCarthy & O'Boyle, Drug Discovery Today, 2026), and manufacturing-facility deficiencies appeared in 65% of 43 approved novel therapeutics with CMC at 51% (Dilek et al., Ther Innov Regul Sci, 2026). Jefferies' analyst read of the full public archive found more than half cite manufacturing and 41% cite product quality (via BioSpace, 11 May 2026).
- In Phase 3's archive analysis, biologic applications carry a manufacturing or quality section in 68.9% of cases (n=119) against 60.5% for small molecules (n=337).
- 31 companies hold three or more published letters and account for 26.3% of the entire archive.
- A recovery rate cannot be computed from the FDA's published archive: the July 2025 tranche was drawn from applications ultimately approved, so pre-2019 letter years read near 100% approved by construction. For recovery, use McCarthy & O'Boyle: 64% of CRL'd NDAs were later approved, 75% for CMC-cited against 44.4% for safety-cited.
- FDA CRL publication paused in April 2026 following a citizen petition and resumed on 10 July 2026 with 14 letters. Current status is tracked at https://ph3.bio/fda-crl-report/statistics/
- The Biotech Capital Report 2026 ranks 517 biotech investors by follow-on rate across 30,486 verified deal events (2015-2026).
- Engagement model: retained, partner-led; every search begins with a diagnostic.

## Author
- Alex Cooke, Founder & CEO. CMC, Quality, and Technical Operations executive search.